A Borrelia burgdorferi Surface-Exposed Transmembrane Protein Lacking Detectable Immune Responses Supports Pathogen Persistence and Constitutes a Vaccine Target

Faith Kung,1,4 Simarjot Kaur,1,4 Alexis A. Smith,1 Xiuli Yang,1 Cara N. Wilder,1 Kavita Sharma,1 Ozlem Buyuktanir,2 and Utpal Pal1

1Department of Veterinary Medicine, University of Maryland-College Park and Virginia-Maryland Regional College of Veterinary Medicine, College Park; and 2Department of Microbiology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey

Borrelia burgdorferi harbors a limited set of transmembrane surface proteins, most of which constitute key targets of humoral immune responses. Here we show that BB0405, a conserved membrane-spanning protein of unknown function, fails to evoke detectable antibody responses despite its extracellular exposure. bb0405 is a member of an operon and ubiquitously expressed throughout the rodent-tick infection cycle. The gene product serves an essential function in vivo, as bb0405-deletion mutants are unable to transmit from ticks and establish infection in mammalian hosts. Despite the lack of BB0405-specific immunoglobulin M or immunoglobulin G antibodies during natural infection, mice immunized with a recombinant version of the protein elicited high-titer and remarkably long-lasting antibody responses, conferring significant host protection against tick-borne infection. Taken together, these studies highlight the essential role of an apparently immune-invisible borrelial transmembrane protein in facilitating infection and its usefulness as a target of protective host immunity blocking the transmission of B. burgdorferi.

Keywords. Borrelia burgdorferi; BB0405; pathogen persistence; transmission-blocking; vaccine.

Lyme disease is a prevalent tick-borne infection in the United States and Europe [1–3]. Newly revised estimates from the Centers for Disease Control and Prevention suggest that there are >300,000 new cases per year in the United States. Although substantial progress has been made regarding proper diagnosis and treatment of Lyme disease [4], a vaccine to prevent human infection is currently unavailable [5]. The causative agent, Borrelia burgdorferi, survives in an enzootic life cycle consisting of arthropod vectors, Ixodes scapularis ticks, and various mammalian hosts, usually wild rodents [6]. Once transmitted from infected ticks to hosts, the spirochetes colonize target tissues—a process supported by the preferential expression of certain gene products that help them adapt to challenges specific to various microenvironments [7, 8]. As many of these gene products lack orthologs outside of the Borrelia clade [9–12], their biological significance is likely to be linked to specialized functions relevant to the intricate infection cycle of spirochetes [13].

In ticks, B. burgdorferi primarily resides within the lumen of the gut [8], and during the subsequent tick-engagement process it undergoes replication, as well as genetic and antigenic alterations required for infection of the mammalian host [14]. Notably, these adaptive changes take place in the gut, where the spirochetes encounter host-derived molecules present in the blood meal, including ingested antibodies. Thus, in a limited number of cases, including after receipt of the former OspA-based Lyme vaccine [15, 16], host antibodies generated against specific borrelial antigens have been shown to inhibit microbial transmission from ticks to host [17]. Some of these gene products, such as BBA52 and OspC, assist spirochetes in migrating from ticks to mice and/or establishing host infection and may play a prominent role in pathogenesis [18–20]. However, given the remarkable genetic diversity of B. burgdorferi [21] and the ability of the spirochete to alter its surface proteome throughout the enzootic cycle, it is difficult to find single protective antigens. Thus, one goal of our ongoing studies is to identify additional stable and conserved borrelial antigens, particularly those that are expressed during tick feeding or mammalian infection and that serve essential roles in infectivity.

The enzootic cycle of Lyme disease spirochetes provides opportunities to target the bacteria either in the mammalian host or the arthropod vector. An advantage of targeting bacteria in the host is that a potential vaccine would only have to induce a memory B-cell response [22], with the infection serving as a proxy booster immunization to induce sufficient antibody levels for neutralization. On the other hand, a benefit of strategies aimed at neutralizing spirochetes in the arthropod vector is that the bacteria’s antigenic profile has not been subjected to the evolutionary selective pressure of the mammalian host’s immune response [23, 24]. In fact, Borrelia antigens expressed in
the vector are mostly conserved [25], and antigenic variation mechanisms appear to be minimally used in the vector [26]. With this strategy, however, the host’s antibodies should be maintained at high levels and stable (over a long duration) without requiring frequent booster immunizations. BB0405 was previously identified as one of the differentially expressed and surface-exposed spirochete antigens that are possible vaccine targets [27]. Here we show that BB0405 supports spirochete infection in mammals and that the antigen is a promising candidate for transmission-blocking vaccines against Lyme disease.

MATERIALS AND METHODS

*B. burgdorferi, Mice, and Ticks*

*B. burgdorferi* infectious isolate B31 A3 was used throughout the present study [19]. Spirochete cultures were grown in Barbour-Stoenner-Kelly H (BSK-H) medium with or without 350 μg/mL kanamycin. *I. scapularis* ticks were reared in the laboratory as described elsewhere [19]. Female C3H/HeN mice aged 4–6 weeks were purchased from the National Institutes of Health. All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee and Institutional Biosafety Committee of the University of Maryland, College Park.

**Polymerase Chain Reaction (PCR) Analysis**

The oligonucleotide sequences for each of the primers used in specific PCR reactions are listed in Supplementary Table 1. Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse transcribed to complementary DNA (cDNA; AffinityScript, Stratagene/Invitrogen), and reverse transcription–PCR (RT-PCR) or quantitative RT-PCR (qRT-PCR) analyses were performed as described elsewhere [19, 28]. Expression of *bb0405* was analyzed in various tissues of C3H/HeN mice (3 animals/group) 14 days after infection (10^5 spirochetes/mouse) or in naive or infected nymphal ticks that fed on infected mice or naive mice (20 ticks/mouse), respectively, as detailed elsewhere [19]. The levels of *B. burgdorferi* *bb0405* transcript in tick and mouse samples were normalized against numbers of flaB transcripts. Cotranscription analyses of *bb0404*, *bb0405*, and *bb0406* were performed with primers that span the genes, indicated in Supplementary Table 1.

**Generation of Recombinant BB0405 and Antiserum and Localization of Native Protein**

*bb0405* was cloned into pGEX-6P-1 (GE Healthcare), using specific primers (Supplementary Table 1), and the recombinant protein without the N-terminal leader sequence was produced in *Escherichia coli*. Expression, purification, and enzymatic cleavage of the glutathione S-transferase (GST) fusion protein were performed as described previously [19, 28]. Polyclonal murine antisera against recombinant BB0405 (without the GST tag) were generated and assessed for titer and specificity, using an enzyme-linked immunosorbent assay (ELISA) and immunoblotting. Localization of native BB0405 in spirochetes was performed as described previously [19, 28].

**ELISA and Immunoblotting**

Plates were coated with recombinant BB0405 or BB0365 or 1 μg of spirochete lysate and blocked with 5% goat serum, followed by addition of either normal mouse serum or *B. burgdorferi*–infected serum (1:500). Serum samples were collected from *B. burgdorferi*–infected mice at various times following infection, with inoculation occurring via needle injection or by tick infestation, as detailed previously [28]. Signals were detected using secondary antibodies and peroxidase substrate (KPL). Immunoblotting was performed as described earlier [28], using murine sera or serum samples collected from 5 patients who tested positive for Lyme disease, as well as from 5 healthy subjects, which were provided by Adriana Marques (National Institute of Allergy and Infectious Diseases).

**Generation of bb0405-Deletion Mutant Isolates of B. burgdorferi**

Genetic manipulation of spirochetes involved routine procedures performed as detailed previously [19, 28]. BB0405-deficient *B. burgdorferi* were generated by homologous recombination, replacing the 546–base pair internal fragment of *bb0405* with a kanamycin resistance cassette, using primers as indicated in Supplementary Table 1. For genetic complementation via reinsertion of a wild-type copy of *bb0405* in the chromosome of the mutant, a construct for allelic exchange was also generated, as detailed in other studies [19, 28]. However, our repeated attempts to complement *bb0405*-mutant isolates were unsuccessful; therefore, for phenotypic analysis, 2 isogenic and independent *bb0405*-mutant clones (designated as Mut1 and Mut2) were included in all studies. For in vitro growth analysis, spirochetes were diluted to a density of 10^5 cells/mL, grown until stationary phase (approximately 10^8 cells/mL), and counted by dark-field microscopy, using a Petroff-Hausser cell counter as detailed elsewhere [19, 28].

**Phenotypic Analysis of bb0405-Mutant Isolates**

To examine the phenotypes of *bb0405* mutants in vivo, wildtype, Mut1, and Mut2 isolates were inoculated into separate groups of mice (3 animals/group; 10^5 spirochetes/mouse). Skin, joint, heart, and bladder samples were isolated 14–21 days of infection, and pathogen burdens were measured by qRT-PCR as detailed previously [19]. Skin and spleen samples were cultured in BSK-H medium for the presence of viable *B. burgdorferi*. For acquisition studies, mice that had been infected for 12 days were allowed to be parasitized by nymphs (30 ticks/group). Ticks were collected after 12 hours of feeding or after repentin. For transmission studies, nymphs were microinjected with 10^5 wild-type or *bb0405*-mutant clones of *B. burgdorferi* as detailed earlier [19]. The infected ticks were fed on naive mice (5 ticks/mouse; 3 mice/group). Engorged ticks were subjected to qRT-PCR analyses and confocal imaging as detailed earlier [19]. At day 10 following tick feeding, all mice were euthanized,
and tissues were isolated and assessed for spirochete burden by qRT-PCR. Portions of skin and spleen were cultured in BSK-H medium.

**Bactericidal Assay**

BB0405 antibodies were tested for their bactericidal activities against *B. burgdorferi* by dark-field microscopy using a regrowth assay as described [28]. Briefly, spirochetes (10^5/mL) were incubated in BSK-H medium (Sigma-Aldrich) supplemented with BB0405 antibodies at 33°C. Normal mouse serum and mouse OspA antibodies (OspA) served as controls. At 48 hours following antisem treatment, spirochetes were enumerated by dark-field microscopy as detailed previously [28].

**Histopathologic Analysis**

*B. burgdorferi*–infected mice underwent histologic evaluation for detection of arthritis as detailed previously. At least 3 ankle joints were collected from each group of mice (3 animals/group) infected with the different isolates and processed for hematoxylin and eosin staining, and signs of arthritis were evaluated as described elsewhere [29].

**Immunization and Infection Studies**

Groups of mice (3–5 animals/group) were immunized subcutaneously either with purified recombinant BB0405 (10 µg/mouse) or phosphate-buffered saline (PBS) mixed in Freund’s complete adjuvant and then boosted with the antigen or PBS in incomplete Freund’s adjuvant. Each animal received 3 immunizations, and serum samples were collected at weekly to monthly intervals. In some experiments, mice (3 animals/group) were infected with a mutant lacking OspA, OspB, and OspC as detailed elsewhere [30]. For protection studies, 10 days after the final boost, mice were challenged with an intradermal injection of *B. burgdorferi* (10^5 spirochetes/mouse), and tibiotarsal joints were collected for detection of arthritis as detailed previously. At least 5 animals/group were infected with the different isolates and processed for histologic evaluation using spirochete lysate and recombinant BB0405.

**Results**

*bb0405 Encodes a Surface-Exposed Outer Membrane Antigen and Is Ubiquitously Expressed In Vivo*

Previous studies suggested that *bb0405* encodes a surface-exposed and transmembrane protein [27], and depending on the culture temperatures, the gene is transcribed at variable levels [31]. To study the potential role of BB0405 in microbial virulence and protective host immunity, we further assessed its cellular localization and antibody accessibility and analyzed its gene expression during infection. Results show that BB0405 is associated with the spirochete membrane (Figure 1A) and is exposed extracellularly, reflected by its rapid sensitivity to proteinase K treatment (Figure 1B). Also, antibodies generated against the B31 isolate recognized similar levels of BB0405 orthologs in other infectious isolates, suggesting its wide conservation across diverse *B. burgdorferi* sensu lato (Figure 1C). Detailed analyses of *bb0405* expression in representative tick- and mammal-specific phases of *B. burgdorferi* infection indicated that the gene is consistently transcribed in vivo (Figure 1D).

**Analysis of the bb0405 Locus and Generation of BB0405-Deficient Spirochetes**

BB0405, which maintains high sequence conservation, possesses 2 recognizable transmembrane motifs and an 18-amino acid hydrophobic N-terminal leader sequence (Figure 2A). Analyses of the chromosomal locus revealed that the gene may be in an operon, which is further supported by RT-PCR–based detection of a single transcript from *bb0404, bb0405*, and *bb0406*, encoding 3 conserved hypothetical proteins of unknown biological significance (Figure 2B). To assess the role of BB0405 in *B. burgdorferi* survival and infectivity, we created targeted deletion mutants via homologous recombination (Supplementary Figure 1). Two clones (designated as Mut1 and Mut2) were selected for further analysis. Both lacked *bb0405* RNA and protein expression without polar effects on transcription of surrounding members of the operon and retained a set of essential endogenous plasmids (Supplementary Figure 2), similar to wild-type spirochetes. Notably, compared with parental isolates, the *bb0405* mutants displayed a significantly slower growth rate in vitro (Supplementary Figure 1). As multiple attempts to complement *bb0405* mutants with a wild-type gene remained unsuccessful, to rule out anomalous effects of genetic manipulation, all subsequent phenotypic studies of mutants included simultaneous and independent analyses of clones Mut1 and Mut2.

**BB0405-Deficient B. burgdorferi Are Not Infectious in Murine Hosts and Ticks**

To determine whether the lack of BB0405 influences spirochete infectivity, C3H/HeN mice (3 animals/group) were inoculated intradermally with equal numbers of wild-type *B. burgdorferi* or one of 2 *bb0405* mutant clones (10^5 spirochetes/mouse). Infection was assessed by qRT-PCR analyses of pathogen burden.
in skin, joint, heart, and bladder samples at day 20 of infection and by organ cultures. The qRT-PCR results indicated that, although wild-type spirochetes persisted in mice, \( bb0405 \) mutants were significantly reduced or undetectable (Figure 3A). Similarly, wild-type spirochetes were isolated by culture of infected spleen, whereas attempts to isolate either of the viable \( bb0405 \) mutant clones remained unsuccessful (data not shown). Mice infected with wild-type \( B. burgdorferi \) seroconverted (Figure 3B), which was reduced in mice infected with \( bb0405 \)-mutant \( B. burgdorferi \). Unlike with wild-type spirochetes, mice infected with \( bb0405 \) mutants displayed less obvious histopathological signs of arthritis (Figure 3C). We next studied the requirement of \( BB0405 \) in supporting the pathogen life cycle in ticks. Little to no \( bb0405 \) mutants were detected in feeding ticks analyzed after 12 hours of host attachment or in fully engorged nymphs, suggesting that \( bb0405 \) mutation impaired \( B. burgdorferi \) acquisition by ticks (Figure 4A). We also compared the ability of the \( bb0405 \) mutants to persist in ticks and transmit from infected ticks to naive mice. As ticks are unable to acquire \( bb0405 \) mutants by the natural engorgement process involving infected hosts (Figure 4A), separate groups of nymphs were microinjected with equal numbers of wild-type or mutant isolates. Injected ticks were allowed to parasitize naive C3H mice (3 animals/group) and were collected as fully engorged nymphs. Spirochete burdens in the ticks were assessed by qRT-PCR and confocal microscopic analyses, which indicated

Figure 1. \( BB0405 \) is a conserved, surface-exposed outer membrane protein constitutively expressed during infection. A, \( BB0405 \) associated with isolated outer membrane or detergent-soluble membrane fractions of cultured spirochetes. \( Borrelia burgdorferi \) protoplasmic cylinder (PC) and outer membrane (OM) fractions were separated by sucrose density gradient centrifugation and immunoblotted with \( BB0405 \), \( FlaB \), and OspA antisera (left panel). \( B. burgdorferi \) lysate was subjected to Triton X-114 partitioning (right panel) and immunoblotted with \( BB0405 \) antibodies or control antibodies. B, \( BB0405 \) is exposed on the surface of \( B. burgdorferi \). Viable spirochetes were incubated with (+) or without (−) proteinase K for various times and processed for immunoblot analyses with antibodies against \( BB0405 \). OspA and \( FlaB \) antibodies served as surface and subsurface controls, respectively (upper panel). Similarly, in an immunofluorescence assay (lower panel), \( BB0405 \) antibodies recognize native protein on the surface of unfixed spirochetes. OspA and \( FlaB \) antibodies served as surface and subsurface controls, respectively. C, \( BB0405 \) is conserved in major infectious strains of \( B. burgdorferi s.s \). Equal amounts of lysates prepared from \( Borrelia \) isolates were immunoblotted with anti-\( BB0405 \) antibodies against \( B. burgdorferi \) B31 isolate. D, \( bb0405 \) is induced during tick feeding. Gene expression was analyzed at representative stages of the experimental tick-mouse infection cycle. RNA was isolated from the skin, heart, and bladder tissues of mice (3 animals/group) 14 days after \( B. burgdorferi \) infection. Naive nymphs were allowed to feed on \( B. burgdorferi \)-infected mice (25 nymphs/mouse) and were collected after repletion. \( B. burgdorferi \)-infected nymphs were fed on naive mice and collected when fully engorged. Murine tissues (skin, heart, and bladder) were collected after 10 days of tick engorgement. Wild-type spirochetes were grown in Barbour-Stoenner-Kelly H medium. RNA from the mouse, tick, and culture samples were analyzed by quantitative reverse transcription–polymerase chain reaction (qRT-PCR) and presented as the number of copies of \( bb0405 \) transcripts per \( flaB \) transcripts. Abbreviations: \( B. afzelii \), \( Borrelia afzelii \); \( B. garinii \), \( Borrelia garinii \).
similar levels of wildtype and bb0405 mutants both in fed tick guts (Figure 4B) and within the salivary glands (Figure 4B), suggesting that BB0405 deficiency does not impair spirochete ability to persist in fed gut or migrate to tick salivary glands. However, 10 days after tick engorgement, little to no B. burgdorferi was detected in multiple tissues of mice parasitized by mutant-injected ticks, indicating that the mutants have a defect in their ability to infect mice via tick-borne infection (Figure 4C).

BB0405 Immunization Evokes Robust and Long-Lasting Humoral Responses Resulting in Protective Immunity Against Tick-Transmitted Infection

As BB0405 is a conserved antigen with antibody-accessible surface epitopes and is important for infection, we next assessed whether BB0405 immunization could elicit protective immunity in mice against tick-borne spirochete infection. To accomplish this, we produced recombinant BB0405 in E. coli and immunized groups of C3H mice (4–5 animals/group) with either purified protein or PBS (control) emulsified with the same volume of adjuvant. An ELISA and immunoblotting performed after final boosting indicated that all mice developed strong antibody titers (>1:450 000) that specifically recognized recombinant BB0405 (Figure 5A). The BB0405 antibodies in immunized rodents also lasted for a long time, as immunoblot analyses using equal amounts of recombinant BB0405 and sera collected at monthly intervals indicated strong responses even at the latest time point examined, 14 months after final boosting (Figure 5B).

To assess vaccine potential of recombinant BB0405, mice (6 animals/group) were immunized as detailed in Figure 5A, and 10 days following final immunization, they were infected with B. burgdorferi via syringe inoculation (10^5 cells/animal). Similar levels of pathogens were detected in all groups (Supplementary Figure 3), suggesting that BB0405 immunization does not affect pathogen burden in infected hosts. To assess whether BB0405 immunization blocks transmission of B. burgdorferi from the vector, mice were similarly immunized with BB0405 (at least 4 animals/group) and then challenged with
B. burgdorferi–infected ticks (5 nymphs/mouse). While spirochete burden in repleted ticks was similar for all groups, a significant reduction was recorded in all tested tissues of mice immunized with BB0405, compared with the controls (Figure 5C), suggesting that BB0405 is a novel target for transmission-blocking Lyme disease vaccines.

BB0405 Antibodies Are Undetectable During Natural Infection and Lack Borreliacidal Activity In Vitro in the Absence of Complement

To further understand BB0405 function in borrelial infectivity and as a vaccine target, we studied whether mice develop BB0405-specific humoral immune responses during infection. Serum samples were collected from mice infected either with syringe-inoculated or tick-transmitted B. burgdorferi at various times representative of early or late infection, and antibody titers against control proteins, La7 [32] and borreliacidal lysate, were measured using an ELISA. While antibody responses against the control subsurface membrane protein La7 and B. burgdorferi were detected, we are unable to record a response against BB0405, irrespective of the infection route (syringe or ticks) or phase of infection (Figure 6A). A subsequent immunoblot analysis further confirmed that, while immunoglobulin M or immunoglobulin G responses against another recombinant borrelial protein, OspC, are detectable, BB0405 remained unrecognizable (Figure 6B). Parallel studies performed using additional mouse strains (B6 and BALB/c) show that neither strain developed antibodies against BB0405 during infection (data not shown). Additionally, immunoblot analysis using 5 serum samples collected from healthy individuals and 5 patients with diagnosed Lyme disease also suggested that BB0405-specific antibody responses were absent during human infection (data now shown). To assess whether surface production of a few known abundant OspS masks BB0405 epitopes and interferes

Figure 3. bb0405 deletion impairs ability of Borellia burgdorferi to persist in mice and cause disease. A, bb0405 deletion dramatically reduces the ability of B. burgdorferi to persist in mice. Animals (3 mice/group) were infected with wild type (WT; black bars) or either of the 2 bb0405 mutants Mut1 (gray bars; upper panel) or Mut2 (gray bars; lower panel). Pathogen levels were analyzed in skin, heart, joint, and bladder samples by measuring copies of B. burgdorferi flaB transcripts at 20 days of infection by quantitative polymerase chain reaction, and data were normalized against murine ß-actin levels. bb0405 mutants were either undetectable or persisted at levels significantly lower than those of corresponding WT pathogens (P<.05). B, bb0405 mutants are less infectious in mice, as assessed by serologic analysis. Serum samples from infected mice collected 14 days after infection were immunoblotted against B. burgdorferi lysate. C, Histopathological examination of the B. burgdorferi–infected murine joints. Mice were immunized with spirochetes, as detailed in Figure 3A, and joint samples were isolated after 14 days and subjected to histologic analysis. Left panel shows lower-resolution (original magnification ×10) images, and right panel reflects higher-resolution (original magnification ×20) images of selected areas from corresponding sections (box). Cellular infiltration is indicated by arrows.
with antibody development, we performed infection studies involving a borrelial mutant that we previously characterized as lacking abundant outer surface proteins OspA, OspB, and OspC [30]. Serum samples collected from groups of mice infected with a larger inoculum of Osp mutants (10⁷ cells/animal) displayed antibody responses against a few antigens in borrelial lysate, but we were still unable to detect presence of anti-BB0405 antibodies (Figure 6C). Despite the ability of BB0405 antibodies to bind to the surface of cultured spirochetes (Figure 1D) and their reported borreliacidal activity in the presence of guinea pig complement [27], no such bactericidal activity was recorded when B. burgdorferi cells were exposed to antibodies against BB0405 in the absence of active complement, although antibodies directed against OspA readily killed the spirochetes (Figure 6D).

**DISCUSSION**

The genome of the Lyme disease pathogen reflects notable structural and functional redundancy, as evidenced by the large number of paralogous genes, as well as experimental demonstrations that certain genes are nonessential for infectivity [6, 11]. Nevertheless, most of the spirochete membrane proteins...
that are differentially produced at a given time and in a specific tissue support bacterial persistence [8]. Our study suggested that, although bb0405 is downregulated in feeding ticks during borrelial transmission and/or within a mammalian host, the gene product is indispensable for infectivity. bb0405 was first identified as a temperature-induced gene [31] that can also be upregulated in mammalian host-adapted spirochetes [27]. This protein represents one of the few examples of spirochete integral outer membrane proteins [33], along with P13, P66, BesC, BamA, and Lmp1 [34], that are predominantly encoded by chromosomal genes [34] serving vital functions in borrelial infectivity [35–37]. The gene product might support replicative growth of spirochetes, as we observed impaired survival of bb0405 mutants, particularly in mid-log phase of culture. Although BB0405 antibodies are unable to exert a microbicidal effect in the absence of complement, their borrelialidial properties in the presence of guinea pig complement, as well as growth-inhibiting effects, were previously reported [27]. Additionally, as described for other borrelial transmembrane proteins, such as P66 [35], BB0405 could have additional or alternate functions, including roles in host-pathogen interaction and B. burgdorferi dissemination through the host.

Being an extracellular pathogen, B. burgdorferi is subjected to the humoral immune response. However, despite detectable expression of the gene during spirochete infection of mice, BB0405 remained invisible to host humoral immune responses. This is remarkable, as a recombinant version of the protein antigen is highly immunogenic and also resulted in long-lasting antibody development. Thus, unlike in cultured spirochetes, BB0405 may be hidden under the microbial surface during mammalian infection or become masked by abundant neighboring outer membrane proteins, as previously described for P66 [38]. This also explains why active immunization of mice with BB0405, despite providing high and specific antibody responses, resulted in nonprotective host immunity against syringe-inoculated spirochetes. On the other hand, notwithstanding a redundant role of BB0405 in spirochete persistence in feeding ticks, immunization of hosts conferred protection against tick-transmitted infection. It is likely that BB0405 antibodies enter the feeding tick gut with
the ingested blood meal. Relative abundance or topological distribution of the antigen on the spirochete surface possibly facilitates antibody binding, blocking of BB0405 function, or interference with other antigens via steric hindrance or another unknown mechanism that ultimately obstructs pathogen transmission to the hosts. Because of the apparent immune invisibility, BB0405 is unlikely to produce an anamnestic response in vaccinated hosts during subsequent spirochete infection. However, such a secondary immune response is possibly of lesser importance for transmission-blocking vaccine candidates like BB0405, as high-titer blocking antibodies must block pathogen dissemination to the tick bite site, preventing early stages of the infection. Identification of conserved and ubiquitously expressed borrelial proteins like BB0405 that are not only critical for microbial virulence but also represent preventive targets against spirochete infection is important for development of second-generation Lyme disease vaccines.

**Supplementary Data**

Supplementary materials are available at http://jid.oxfordjournals.org. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.

**Notes**

**Acknowledgments.** We thank John Anderson and Adriana Marques for their assistance with this study.

**Financial support.** This work was supported by the National Institute of Allergy and Infectious Diseases (award R01AI080615 to U. P.).
Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
15. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1999; 250:553–6.